Pentoxifylline decreases in vivo and in vitro tumour necrosis factor- alpha (TNF-α) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL)

Clinical and Experimental Immunology

Volumn 111, Issue 2, 1998, Pages 300-308

  Sampaio, E P ^a   Moraes, M O ^a   Nery, J A C ^a   Santos, A R ^a   Matos, H C ^a   Sarno, E N ^a,b  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Erythema nodosum leprosum; Pentoxifylline; RT PCR; Thalidomide; Tumour necrosis factor alpha

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; PENTOXIFYLLINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG MECHANISM; ERYTHEMA NODOSUM LEPROSUM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LEPROMATOUS LEPROSY; LEPROMIN TEST; MALE; MONONUCLEAR CELL; MYCOBACTERIUM LEPRAE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PUNCH BIOPSY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; CELLS, CULTURED; ERYTHEMA NODOSUM; FEMALE; GENE EXPRESSION; HUMANS; LEPROSY, LEPROMATOUS; MALE; MIDDLE AGED; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031910627     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00510.x     Document Type: Article

References (39)

1. Fiers W. Biologic therapy with TNF. Preclinical studies. In: De Vita Jr VT, Hellman S, Rosenberg SA, eds. Biology therapy of cancer, 2nd edn. Philadelphia: JB Lippincott Co., 1995:295-327.
2. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325:467-72.
3. Tetta C, Camussi G, Modena V, Di Vittoria C, Baglioni C. Tumor necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990; 49:665-7.
4. Sarno EN, Grau GE, Vieira LMM, Nery JA. Serum levels of tumour necrosis factor-alpha and interleukin-1β during leprosy reactional states. Clin Exp Immunol 1991; 84:103-8.
5. Parida SK, Grau GE, Zahfer SA, Mukherjee R. Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions. Clin Immunol Immunopathol 1992; 62:23-27.
6. Foss NB, Oliveira EB, Silva CL. Correlation between TNF production, increase of plasma C-reactive protein level and suppression of T lymphocyte response to concanavalin A during erythema nodosum leprosum. Int J Lepr 1993; 61:218-26.
7. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon γ induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992; 175:1729-37.
8. Sampaio EP, Duppre NC, Moreira AL, Nery JAC, Sarno EN. Development of giant reaction in response to PPD skin test in lepromatous leprosy patients. Int J Lepr 1993; 61:205-13.
9. Khanolkar-Young S, Rayment N, Brickell PM, Katz DR, Vinayakumar S, Colston MJ, Lockwood DNJ. Tumour necrosis factor-alpha (TNFα) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol 1995; 99:196-202.
10. Sampaio EP, Kaplan G, Miranda A, Nery JAC, Miguel CP, Viana SM, Sarno EN. The influence of thalidomide on the clinical and immunological manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168:408-14.
11. Hussain R, Lucas SB, Kifayet A. Clinical and histological discrepancies in diagnosis of ENL reactions classified by assessment of acute phase proteins SAA and CRP. Int J Lepr 1995; 63:222-30.
12. Howard M, O'Garra A. Biological properties of interleukin 10. Immunol Today 1992; 13:198-200.
13. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-20.
14. Wanidworanun C, Strober W. Predominant role of tumor necrosis factor-α in human monocyte IL-10 synthesis. J Immunol 1993; 151:6853-61.
15. Sieling PA, Abraams JS, Yamamura M, Salgame P, Bloom BR, Rea TH, Modlin RL. Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T cell responses in leprosy. J Immunol 1993; 150:550-10.
16. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, Modlin RL. Defining protective responses to pathogens: cytokine profile in leprosy lesions. Sci 1991; 254:277-9.
17. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
18. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Ehlers S, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on TNFα by enhancing mRNA degradation. J Exp Med 1993; 177:1675-80.
19. Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol 1994; 30:60-21.
20. Doherty GM, Jensen C, Alexander R, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surg 1991; 110:192-8.
21. Zabel P, Schonharting MM, Wolter DT, Schade UF. Oxpentifylline in endotoxaemia. Lancet 1989; 23:1474-7.
22. Dezube BJ, Sherman ML, Fridovich-Keil JL, Allen-Ryan J, Pardee AB. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol Immunother 1993; 36:57-60.
23. Gramnger W, Thalhammer F, Lockr G. Pentoxifylline in cerebral malaria. J Infect Dis 1991; 164:829.
24. Sarno EN, Nery JAC, Garcia CC, Sampaio EP. Is pentoxifylline a viable alternative in the treatment of ENL? Int J Lepr 1995; 63:570-1.
25. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr 1966; 34:255-73.
26. Ehlers S, Smith KA. Differentiation of T cell lymphokine gene expression: the in vitro acquisition of T cell memory. J Exp Med 1991; 173:25-36.
27. Friedman M. The use of ranks to avoid the assumption of normality implicit in the analysis of variance. J Am Assoc 1937; 32:675-701.
28. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J, Kunkel S. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Bioch Biophys Res Commun 1988; 155:1230-6.
29. Sarno EN, Sampaio EP. Role of inflammatory cytokines in tissue injury in leprosy. Int J Lepr 1996; 64:S69-S74.
30. Barnes PF, Chatterjee D, Brennan PJ, Rea TH, Modlin RL. Tumor necrosis factor production in patients with leprosy. Infect Immun 1992; 60:1441-6.
31. Dezube BJ, Pardee AB, Chapman B et al. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with Aids. J Acquir Immune Defic Syndr 1993; 6:787-94.
32. Dezube BJ, Fridovich-Keil JL, Lange RF, Pardee AB. Pentoxifylline and wellbeing in patients with cancer. Lancet 1990; 335:662.
33. Biswas DK, Dezube BJ, Ahlers CM, Pardee AB. Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-κB action. J Acq Immune Defic Syndr 1993; 6:778-86.
34. Enres S, Fulle H-J, Sinha B, Stoll D, Dinarello CA, Gerzer R, Weber PC. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1β by human mononuclear cells. Immunol 1991; 72:56-60.
35. Duncan MR, Hasan A, Berman B. Pentoxifylline, pentifylline, and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. J Invest Dermatol 1995; 104:282-6.
36. Zabel P, Schade FU, Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. Immunobiol 1993; 187:447-63.
37. Fiorentino DF, Zlotnik A, Mosmann TR, Howard MH, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147:3815-22.
38. D'Andrea A, Aste-Amezaga M, Valianten NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ-production by suppressing natural killer cell stimulatory factor/ IL-12 synthesis in accessory cells. J Exp Med 1993; 178:1041-8.
39. Navarro J, Punzón MC, Pizarro A, Fernández-Cruz E, Fresno M, Muñoz-Fernández MA. Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumour necrosis factor synthesis or nuclear faclor-kB activation. AIDS 1996; 10:469-75.